GAINESVILLE, Fla. — February 14, 2012 — Quick-Med Technologies, Inc., a life sciences company that
is developing innovative technologies for the healthcare and consumer markets, announced today that
it has amended the license previously granted to Viridis BioPharma to include a new antimicrobial
polyurethane foam dressing that utilizes Quick-Med’s proprietary NIMBUS® technology and that
Viridis has received approval from the Food and Drug Administration of India to manufacture and
market the dressings. This is the first of several NIMBUS advanced wound care formats that are in
Viridis BioPharma, an India-based manufacturer and marketer of medical devices, plans to
commercialize a broad line of wound care products that incorporate Quick-Med’s unique NIMBUS
antimicrobial technology including gauze pads, gauze rolls and foam dressings, under the trade name
of Microgauze™ and Microfoam™ wound dressings. Viridis has completed a manufacturing expansion to
produce the new dressings and plans to have the dressings on the market before the end of the
second quarter of 2012.
Laboratory testing has demonstrated that Microfoam is highly effective against even the most
difficult Gram-negative species of pathogenic bacteria. Additionally, Viridis has conducted a pilot
clinical trial in Mumbai that confirmed continuous infection control and the exudate absorption
property of this non-leaching antimicrobial dressing over days of use.
“Expanding our NIMBUS antimicrobial technology to advanced wound care formats marks an
important milestone for Quick-Med,” said J. Ladd Greeno, Quick-Med’s CEO. “We are excited to be
partnering with Viridis. India’s large wound care market represents a significant opportunity for
Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature.”
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, “We see this approval to manufacture
and market Microfoam dressings that was developed by Viridis using NIMBUS Technology as a big step
in improving wound care in India and other markets.”
Quick-Med is seeking additional licensees for this new technology. NIMBUS foam production can
be easily implemented at a company’s current manufacturing location, or arrangements can be made
for Viridis to provide finished product under a toll manufacturing agreement.
While NIMBUS antimicrobials remain at full strength, the active agent in most other
antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the
risk of irritation or interference with healing in products such as wound dressings and textile
applications in which the treated material is next to or used on the skin.
The bonding of an antimicrobial to a substrate is a paradigm shift from the current
state-of-the-art which fosters release of the active agent. The value of a non-leaching
antimicrobial is that it does not allow depletion of the active agent which can lead to damage to
human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate
the development of bacterial resistance.
Posted on February 21, 2012
Source: Quick-Med Technologies